CLU and breast cancer: These findings identify CLU as an upstream regulator of a pro-metastatic adhesion-cytoskeleton signaling in BC, selectively operative in EMT-engaged, basal-like cells, highlighting the importance of patient stratification for CLU-targeted therapeutic strategies.